Abstract: Gene therapy has been investigated in many aspects of plastic and reconstructive surgery. These areas ultimately involve various forms of tissue healing and the manipulation of bony and soft tissues to reconstruct defects secondary to neoplastic and congenital disorders and trauma. Most research has been limited to animal studies with the exception of clinical trials on the use of gene therapy in lower leg ulcer healing and as an adjunct to advanced recurrent squamous cell carcinoma of the head and neck. Overall, these preliminary studies have produced optimistic results. With the development of more efficient and safer delivery systems, the application of gene therapy in plastic surgery could become more widespread, especially in combination with tissue engineering technology.
INTRODUCTION
Despite the large number of gene therapy clinical trials in various areas of medicine, plastic and reconstructive surgery has been slow to adopt this technology in patients. Plastic and reconstructive surgery deals with a wide range of clinical problems, ultimately involving various types of tissue healing and vascularisation. These areas include skin, bone, tendon and nerve healing, the management of cutaneous oral and mucosal tumours, the reconstruction of neoplastic and traumatic defects and various congenital disorders such as craniosynostosis. Many of the molecular events in these conditions are still being unravelled, are probably more complex than previously thought, and there are few life threatening conditions in plastic surgery that would currently justify a clinical trial until the transfer efficiency and safety of vectors has been verified. The recently published adverse effects of retrovirally treated severe combined immune deficiency infants have particularly highlighted the importance of a cautious approach in this area [Check E, 2002 , Check E, 2003 . Table 1 summarises current gene therapy clinical trials submitted to the Recombinant DNA Advisory Committee [Genetic Modification Clinical Research Information System, 2004] .
The purpose of this review is to highlight the areas of plastic and reconstructive surgery in which gene therapy is being investigated and may have a role in the future. These include wound, tendon, nerve and bone healing, reconstructive tissue flaps, craniosynostosis and haemangioma therapy and as an adjunct to recurrent regional squamous cell carcinoma of the head and neck. Perhaps the most exciting application of gene therapy in plastic surgery is in the area of tissue engineering. Surgeons have always sought to increase their armentarium in the management of clinical problems. In particular plastic surgeons have strived to identify the best tissue to use to reconstruct anatomical defects, while minimising donor site morbidity. Tissue engineering offers the potential to produce tissue ex vivo and in vivo that functionally and aesthetically resembles the original tissue to be replaced. Preliminary research shows that the inducive effects of growth factors are required for successful tissue engineering, which could be achieved using gene therapy. Table 2 summarises important genes investigated and used in gene therapy in several areas of plastic and reconstructive surgery.
WOUND HEALING
Wound healing is a complex cascade of overlapping processes that occur in a regulated fashion. Clinically wounds heal by a combination of epithelialization, connective tissue deposition and contraction. Surgical intervention facilitates wound healing and can be described as healing by primary intention (suturing or stapling wound edges together), delayed primary closure (contaminated wounds that are closed surgically after a period of time) and secondary intention (no mechanical coaptation of wound edges and primarily heals by contraction) [Mast and Cohen, 2000] . On a cellular level, tissue injury initiates the process of haemostasis (bleeding, coagulation), inflammation, proliferation (cell replication, angiogenesis, epithelialization) and remodelling (extracellular matrix synthesis) ( Fig. 1 ) [Grabb and Smith, 1997a; Mast and Cohen, 2000] . Growth factors are responsible for modulating various processes in wound healing and an understanding of their roles allows for the manipulation of wound healing. Growth factors involved in wound healing include platelet derived growth factor (PDGF), transforming growth factor-β (TGF-β), the vascular endothelial growth factors (VEGF-A, VEGF-B), transforming growth factor-α (TGF-α), epidermal growth factor (EGF), interleukins, tumour necrosis factor (TNF), leukocyte-derived growth factor, connective tissue growth Phase I trial to evaluate the safety of HS.020CMVPDGF-B and limb compression bandage for the treatment of venous leg ulcer (Trial A) .
Wound healing
A dose escalating phase I study of Ad PDGF-B/GAM in the treatment of diabetic ulcers of the lower extremity (Steed DL. Protocol number 0010-421).
Hand repair
Single dose-ranging study of formulated hIGF-I plasmid in subjects with cubital tunnel syndrome (Netscher D. Protocol number 9703-180).
Autologous, irradiated, cancer cells (Breast cancer, head and neck cancer, and soft tissue sarcoma) transduced ex vivo with an adenovirus vector (Adv/GM-CSF) expressing Granulocyte-Macrophage Colony Stimulating factor gene (Suzuki T.
Protocol number 9806-257).
A phase II study of the safety and efficacy of Allovectin-7 immunotherapy for the treatment of primary resectable squamous cell carcinoma of the oral cavity or oropharynx (Carroll W. Protocol number 0011-432).
Multi-center open-label randomised study to compare the overall survival and safety of bi-weekly intratumoral administration of RPR/INGN 201 versus weekly methotrexate in 240 patients with refractory SCCHN (Agarwala SS. Protocol number 9912-366).
IL-12 gene therapy using direct injection of tumour with genetically engineered autologous fibroblasts (Lotze M. protocol number 9406-081) [Kang et al. 2001] .
Phase II study of immunotherapy by direct gene transfer with Allovectin-7 for the treatment of recurrent or metastatic SCCHN (Gluckman JL, Gleich LL. Protocol number [Gleich et al. 2001] .
Multi-center open-label, randomised study to compare the effectiveness and safety of intratumoral administration of RPR/INGN 201 in combination with chemotherapy versus chemotherapy alone in 288 patients with recurrent SCCHN (Arquette M. Protocol number 0009-412).
A multi-center, open-label, multiple administration, rising dose study of the safety, tolerability, and efficacy of IL-12 Gene Medicine in patients with unresectable or recurrent/refractory SCCHN (Colevas AD. Protocol number 9907-332).
IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts (A phase II study) (Agarwala SS. Protocol number 9801-227).
Clinical protocol for modification of tumour suppressor gene expression in HNSCC with an adenovirus vector expressing wild-type p53 [Clayman GL. 1999] .
Multi-center open-label randomised study to evaluate effectiveness and safety of two treatment regimens of Ad5CMV-p53 administered by intra-tumoral injections in 78 patients with recurrent SCCHN (Breau R. Protocol number 9709-214).
Head and Neck Cancer
Study of the safety and efficacy of Allovectin-7 by direct intratumoral injection in advanced HNSCC [Gleich et al. 1998 ].
Multi-center open-label study to evaluate the effectiveness and safety of Ad5CMV-p53 administered by intra-tumoral injections in 39 patients with recurrent SCCHN (Dreicer R. Protocol number 9712-226).
( A multi-center study of E1A lipid complex for the intratumoral treatment of patients with recurrent HNSCC [Villaret et al. 2002] .
A phase I trial of intratumoral antisense EGFR DNA and DC-Chol liposomes in advanced oral squamous cell carcinoma (Grandis JR. Protocol number 9902-285).
A multi-center, Phase II study of intratumoral injections of E1A-lipid complex and re-irradiation for treatment of patients with recurrent HNSCC (Anthony S. Protocol number 0012-438).
Phase I trial of intratumoral EGFR antisense DNA in advanced HNSCC (Grandis JR. Protocol number 0304-576).
Phase I/pilot study of intralesional immunotherapy with a recombinant Avipox virus engineered to express a triad of co-stimulatory molecules in patients with advanced SCCHN (Van Waes C. Protocol number 0010-429).
Multi-center open-label, multiple administration, study of the safety, tolerability and efficacy of IFNα/IL-12 combination gene therapy in patients with SCCHN (McQuone SJ. Protocol number 0002-378).
Clinical protocol for wild-type p53 gene induction in premalignancies of squamous epithelium of the oral cavity via an adenoviral vector (Clayman GL. Protocol number 0101-445).
Open-Label, multiple administration, study of the safety, tolerability, and efficacy of IFN-alpha Gene medicine in Patients with malignant angioendothelioma (Baker, LH. Protocol number 9910-351). Trial for primary untreated HNSCC UICC Stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol [Wollenberg et al. 1999] .
Active immunization of patients with carcinoma of the oral cavity or oropharynx with interleukin-2-secreting semiallogeneic human carcinoma cell line transfected with DNA from autologous tumor (Phase I study) (Johnson JT. Protocol number 0112-511). Fig. (1) . Summary of the phases of wound healing, associated cellular infiltration and extracellular matrix involvement with growth factor production. ECM, extracellular matrix; GAG, glycosaminoglycans; IL-1, interleukin -1. Abbreviations of growth factors are described in the Glossary and Table 2 . [Grotendorst et al., 1985] . The application of the human recombinant PDGF-BB to wound healing has produced favourable responses, although the short half-life of the protein and the use of relatively inefficient delivery systems have necessitated the use of multiple large doses to achieve a clinical effect [Mustoe et al., 1994] . The efficacy of human PDGF-BB in a gel form (becaplermin), has been demonstrated in the management of healing diabetic neuropathic ulcers [Weiman et al., 1998 , Embil et al., 2000 . The addition of PDGF-BB to subsequent surgery also results in a greater proportion of healed pressure ulcers compared to placebo [Kallianinen et al., 2000] .
VEGF-A is fundamental to endothelial cell survival, proliferation and migration, increased vascular permeability and inhibition of apoptosis [Senger et al., 1983; Leung et al., 1989; Nagy et al., 1995; Ferrara and Davis-Smith, 1997; Spyridopoulos et al., 1997; Gerber et al., 1998a; Gerber et al., 1998b] . There are several isoforms of 189, 165, 145, 121) of which VEGF-A165 and 121 have been the most intensively investigated. The critical role of VEGF-A in blood vessel formation has led to numerous animal studies in wound healing. Topical VEGF-A has recently been found to improve wound closure by 25% in a diabetic mouse model, perhaps because of reduced VEGF-A production by macrophages, neutrophils and keratinocytes in diabetic mice [Kirchner et al., 2003] . Similar findings of decreased VEGF-A in diabetic wounds have been observed in other cutaneous wound healing models [Kampfer et al., 2001] .
Despite the promising results of protein therapy, the limited time of cytokine effect and the expense of production and application of cytokines has led to the development of gene delivery systems that produce a more prolonged effect. Gene vectors produce a higher transduction efficiency and are more cell-selective. Augmented wound healing has been documented following gene transfer of VEGF-A using viral vectors. An in vitro transduction efficiency of more than 95% has been reported with adenoviral vectors in human skin cells and greater than 90% gene transduction efficiency of dermal fibroblast and epidermal keratinocytes of human skin using vectors based on the human immunodeficiency virus (HIV, lentivirus) [Kozarsky and Wilson, 1993; Chen et al., 2003] . Wounds transduced with adenoviral vectors can produce transgene expression for up to two weeks [Liechty et al., 1999a] . The limited duration of transgene expression avoids or diminishes the potential side effects from the adenovirus or longterm overexpression of the transgene. Overexpression of VEGF-A and PDGF-BB could theoretically result in the formation of angiomas and hypertrophied wounds respectively. The adenovirus may also elicit an acute inflammatory response, which has proved to be useful as it may augment the inflammatory phase of wound healing [Crombleholme, 2000] . Single dose adenoviral transfer with PDGF-BB to ischaemic rabbit excisional wounds increased wound reepithelialization [Liechty et al., 1999b] . The PDGF-BB adenoviral treated wounds were characterised by increased granulation tissue formation, extracellular matrix production and angiogenesis. Adenoviral clinical studies with PDGF-B in patients with lower limb ulcers are currently underway ( Table 1) .
Non-viral gene delivery approaches have also been applied to wound healing, but are associated with a low transfection efficiency. Various transfection reagents (Lipofectamine of Gibco, Superfect of Quiagene, Cytofectin of Bio-Rad or calcium phosphate precipitation) in human dermal fibroblast and epidermal keratinocytes under optimised conditions in in vitro studies have never achieved greater than 20% green fluorescent protein expression in dermal fibroblasts or greater than 30% in keratinocytes [Chen et al., 2003] . The development of specific transport molecules that allow entry of the plasmid to the nucleus of a cell and subsequent protein product formation could potentially improve transfection efficiency [Subramanian et al., 1999] . The gene gun can increase the transfection efficiency of plasmids over injections [Udvardi et al., 1999] , achieving DNA delivery using pressure to accelerate plasmid DNA coated microparticles to penetrate cells. It can transfect approximately 2 cm 2 per application [Davidson et al., 2000] . EGF has been applied via a gene gun to porcine partial thickness wounds and has increased the rate of reepithelialization [Andree et al., 1994] . Similarly, following application of a single dose of PDGF to a rat incisional wound model, wound strength at two weeks increased by 75-100% compared to controls [Eming et al., 1999] . The biology of wound healing is complex making it difficult to predict the best combinations and doses of candidate genes for over-expression. The small number of patients recruited to individual clinical trials often means that they are underpowered to identify real effects.
Keloid scarring is a disfiguring abnormal form of wound healing defined as a scar that grows beyond the confines of the original wound margin. Keloid has a tendency to occur in certain racial groups, such as Blacks, Hispanics and Orientals [Tuan and Nichter, 1998 ]. It is also associated with trauma, infections and foreign-body reactions and has a tendency to occur in certain anatomical areas such as the midchest, upper back, earlobes and shoulders [Muir IF, 1990] . The optimal treatment still remains undefined [English and Shenefelt, 1999] . The molecular biology of keloid scars has revealed an association between keloid formation and TGF-β expression, increased resistance to apoptosis and abnormal collagen gene expression. Since keloid formation is unique to humans the majority of studies have been conducted in in vitro models. Recently the first application of gene therapy to keloid formation was published [Ma et al., 2003] . The authors demonstrated that they could successfully transduce human keloid tissue with adeno-associated virus encoding Escherichia coli β-galactosidase 4 weeks after injection into the dermis of an ex vivo skin organ culture model. As the molecular biology of keloid formation is better understood there may be a role for gene therapy in the treatment armamentarium of this form of scarring.
GENE THERAPY IN RECONSTRUCTIVE FLAPS
A flap is a layer of skin or other tissue separated from its deeper structures and transferred either locally or distantly to cover a defect caused by surgery, trauma or disease. The base of the flap provides its blood supply. The arterial and venous perfusion of the distal end of such flaps may be compromised and result in necrosis, especially in diabetics and those on corticosteroid therapy. The augmentation of the blood supply of flaps that are designed to cover large defects or those in areas notorious for poor distal perfusion, such as on the lower limbs would be an attractive adjunct to surgery. Reconstructive flaps play a fundamental role in plastic surgery as they allow defects to be filled with autogenous tissue.
Initial studies in flap survival were performed using protein cytokine therapy. FGF and VEGF-A have both been investigated and resulted in improved survival in skin and muscle flaps [Ishiguro et al., 1994; Kryger et al., 1999; Banbury et al., 2000; Kryger et al., 2000; Zhang et al., 2001] . The most effective approach to cytokine delivery has not been defined. Systemic administration of recombinant VEGF-A via the femoral artery into a ventral epigastric island rat flap produced a larger increase in flap survival when compared to local injection [Tucci et al., 2001] . In our laboratory, intradermal application of recombinant VEGF-A165 in the epigastric island rat flap model produced more favourable results than systemic administration [O'Toole, unpublished] . Such variation may be partly due to technical differences in flap design and surgical technique.
The promising results with cytokine application have prompted the administration of these genes to flaps. Liposomal delivery of cDNA encoding human VEGF-A121 improved skin flap survival when administered by the arterial pedicle [Taub et al., 1998a] . This effect appeared to be related to the production of smaller blood vessels in the area of ischaemia. Treated flaps need sufficient time to development an adequate blood supply to overcome more significant ischaemia such as ligation of the pedicle of the flap [Taub et al., 1998b] . In our laboratory we have demonstrated an increase in skin flap survival in a rat epigastric ventral flap model using plasmid VEGF-A165 and VEGF-B167 compared to controls [O'Toole et al., 2002] . These findings have led us to explore the treatment of similar flaps with viral vectors. Intradermal administration of an adenovirus encoding VEGF-A165 into a skin flap rat model improved overall skin flap survival [Lubiatowski et al., 2002] . Interestingly adenovirus-mediated VEGF-A121 gene transfer to nonischaemic skeletal muscle has successfully produced an angiogenic response and attenuated any haemodynamic deficit of subsequent surgically induced ischaemia [Gowdak et al., 2000] . This is particularly important in reconstructive surgery where routinely wellperfused skin and muscle flaps are raised with their vascular pedicle and transferred to the defect site. The augmentation of angiogenesis in well-perfused normal tissue may result in a flap that is more resistant to ischaemic injury. Successful pre-treatment of such reconstructive flaps has already been demonstrated using protein therapy in animal Transverse Rectus Abdominis Myocutaneous Flap models [Zhang et al., 2001; Seify et al., 2003] . Prefabricated flaps stimulate angiogenesis by implantation of a vascular pedicle in tissue to be used for a planned reconstruction [Morrison et al., 1990] . A major advantage of prefabricated flaps is that they can be designed in expendable tissue and transferred either on a vascular pedicle or as a free flap to a recipient site [Morrison et al., 1997; Orringer et al., 1999] . The combination of flap prefabrication with, in one study, tissue expansion and in another, the delay procedure (modifying a flap prior to transfer, by raising a skin flap on two sides, resulting in increased vascularity of the flap from the attached two sides and division of the third side at a delayed stage) proved effective at improving flap survival [Maitz et al., 1994] . Administering bFGF to prefabricated flaps has also been shown to improve flap survival in a rabbit ear model [Duffy et al., 1996] . The use of alternative angiogenic gene therapy has not yet been attempted in a similar model.
The delay procedure is performed to increase the vascularity of the flap and can be achieved surgically or by pharmacologic intervention. Factors thought to be involved include (1) an alteration in sympathetic tone secondary to sympathectomy after raising the flap, (2) an increase in vascularity of the flap with the formation of new vessels and reorientation of established vessels, (3) the dilation of choke vessels that connect adjacent angiosomes (three-dimensional composite tissue blocks that are each supplied by its own artery and vein) and (4) the possibility of conditioning or hardening to ischaemia by metabolic alterations [Smith and Pribaz, 2000] . Since angiogenesis is fundamental to this phenomenon [Jonsson et al., 1988; Arranz Lopez et al., 1995] , gene therapy could in theory, be employed to enhance new vessel formation in "delayed tissue". Theoretically, by using VEGF gene therapy to augment the native cytokine expression of the delay phenomenon, the time needed between operations could be reduced and larger flaps planned. The fact that VEGF-A expression is upregulated in artificially expanded tissue suggests a further use of exogenous genes [Lantieri et al., 1998 ]. Application of gene therapy to enhance the angiogenesis and cellular proliferation that follows tissue expansion may allow more rapid expansion to be prescribed. Tissue expansion of areas such as the forehead is noted sometimes to be painful [Cole et al., 1991] . Perhaps improving tissue healing and remodelling with exogenous agents may make the experience less uncomfortable for patients.
HAND SURGERY
The management of hand trauma and disease requires meticulous surgical repair of tendons, ligaments, nerves, joints, cartilage and bone in conjunction with intensive physiotherapy. Full recovery of hand function is not always achievable, particularly in elderly patients.
Tendons may heal through adhesion formation from surrounding tissues or through intrinsic healing following injury. Healing by adhesion formation involves the influx of erythrocytes, platelets and fibrin bridge formation. Inflammatory cells and mesenchymal cells migrate over this fibrin bridge, followed by granulation tissue formation with fibroblasts, neovessels and collagen deposition. This form of healing is encouraged by immobilisation. Tendon remodelling occurs in the final phase as adhesive bridges become thin and flexible facilitating tendon mobilisation [Strickland, 1999; Lawrence and Kashyap, 2000] . Intrinsic tendon healing relies on an adequate blood supply via vessels that run in a vascular mesentery (vinculum) within the sheath. These are easily avulsed when flexor tendons on the volar surface of the palm retract after injury. The blood supply is also derived from the tendon's osseous attachment and synovial and extracellular tissue fluid provides nutrients and act as a lubricant during movement. Extrasynovial tendons receive their blood supply from peritendinous soft tissue. Fibroblasts, primarily from the epitenon (internal layer of the tendon bilayered sheath) migrate to the site of injury and collagen is laid down. PDGF and EGF are thought to be involved in the migratory and synthetic activity [Lawrence and Kashyap, 2000] . Stress on tendons influences the favourable remodelling of scar in healing tendons provided the area of union is stable. Tendon strength, size and vascularity can be increased with exercise. Stressed tendons heal faster, have a better excursion and regain tensile strength faster than non stressed tendons, with a reduction in adhesion formation [Grabb and Smith, 1997b] . Tendon healing is influenced by several factors relating to the extent of injury, the degree of bacterial contamination and the degree of tendon separation and vascularity. Intrinsic healing is compromised in the presence of extensive contaminating crush injuries with substantial gapping between tendon ends. Optimal treatment requires meticulous surgical technique with accurate apposition of tendon ends and primary repair within a few days of injury, followed by postoperative controlled mobilisation. [Lawrence and Kashya, 2000] . Gene therapy approaches to the promotion of tissue repair and early hand mobilisation are being explored to minimise complications of stiffness and immobility.
Tendons are made up of abundant type I collagen and small amounts of type II and IV collagen and elastin. They contain occasional tenocytes, synovial cells and fibroblasts. The bone morphogenic proteins (BMP) (BMP-2, BMP-13, BMP-14) and PDGF-B have a role in tendon healing, while increased TGF-β mRNA levels and their receptors (TGF-β RI, RII, RIII) have been detected in tendons and their sheaths associated with scarring [Gelberman et al., 1985; Chang et al., 1997; Ngo et al., 2001] .
Bone morphogenic proteins were first described by Marshall Urist in 1960 and cloned in 1987 [Reddi, 1997] . In addition to their originally described role in fracture repair, they are critical to tendon healing. Mutations in GDF-5 (growth and differentiation factor 5, also known as BMP-14 and CDMP-1 (cartilage derived morphogenic protein-1)) cause altered tendon morphology [Gruneberg and Lee, 1973] and mechanical properties [Mikic et al., 2001] . CDMP-1 (GDF-5/BMP-14) and CDMP-2, also known as GDF-6 and BMP-13 are bone inducers but they can also induce tendonlike tissue in extraskeletal implants. Application of CDMP-1 and CDMP-2 to a rat tendon achilles transected model, increased the amount of tendon callus and the strength of the repairing tendon [Aspenberg and Forslund, 1999; Forslund and Aspenberg, 2001] . In another rat model, the application of CDMP-2 on a collagen sponge to a 3 mm achilles tendon defect reduced the healing time by a third and resulted in an increase in tendon strength following CDMP-2 injection into the wound haematoma. This study demonstrated both an increase in the size and strength of the tendon [Aspenberg and Forslund, 2000] . GDF-5 has also been applied to suture material (absorbable polyglactin suture -Vicyrl TM ) at a dose of one µg/cm and applied to a rat achilles tendon model, resulting in improved tendon strength and stiffness for up to four weeks from the time of repair [Rickert et al., 2001] . A minimal inflammatory reaction and thicker tendon was thought to be due to the stimulatory effect of GDF-5, while delayed differentiation and maturation of type III collagen repair tissue to mature type I collagen was observed. Unfortunately cartilaginous nodules were observed in the experimental group.
Gene transfer using various viral vectors has been performed in tendons and ligaments to produce similar effects. Direct percutaneous injection of adenovirus encoding laciferase Z (LacZ) into rabbit tendons has resulted in gene expression immediately adjacent to the injection site and in the epitenon sheath [Gerich et al., 1996] . Allotransplantation of transduced tendon fibroblasts with a retrovirus encoding LacZ in a similar model produced LacZ expression throughout the tendon. Gene expression in both cases persisted for at least 6 weeks [Gerich et al., 1996] . Following the in vitro transduction of chicken tendon cells with adenoviral vectors encoding human BMP-12 (AdBMP-12), a 30% increase in collagen type I was observed [Lou et al., 2001] . In an in vivo Leghorn chicken lacerated flexor profundus tendon model in which the tendon was sutured and treated with an intrasynovial space injection of AdBMP-12, the tensile strength and stiffness of the repaired tendon was increased two-fold [Lou et al., 2001] . There was no evidence of bone formation at 6 weeks suggesting that in vivo and in vitro BMP-12 had no osteogenic function [Lou et al., 1999; Lou et al., 2001] . GDF 5, 6, and 7 were found to induce the formation of dense connective tissue when implanted intramuscularly or ectopically in rats, suggesting that progenitor cells, which can be influenced to differentiate along a tendon/ligament pathway under the appropriate signal, exist in adult animals at these sites. Ectopic tendon and ligament like structures have been induced with an adenoviral GDF-6/BMP-13 vector after intramuscular injection in nude rats [Helm et al., 2001] . The authors found evidence of endochondral osteogenesis induction and an increase in angiogenesis. Nude rats were followed-up for 100 days with foci of fibrocartilage detectable from 21 days. The osteogenic potential of BMP-13 remains controversial. In an alternative study on the potential of recombinant BMP-13 to induce neotendon/neoligament formation, the authors were unable to detect bone or cartilage formation [Wolfman et al., 1997] .
Gene therapy has been combined with cell-mediated therapy (involving the administration of fully differentiated fibroblasts or mesenchymal cells) to examine augmentation of tendon healing. Direct injection of adenoviral vectors encoding β-galactosidase administered together with transduced myoblasts into the anterior cruciate ligament has produced detectable marker in cells for up to 6 weeks, while the injected myoblasts had fused and formed myofibres in the ligament after 1 week [Menetrey et al., 1999] . The authors concluded that the poor vascularity and dense structure of ligaments acted as an unfavourable environment for fibroblast ex vivo therapy. Direct viral injection into rabbit medial collateral and anterior cruciate ligaments produced better expression of marker gene than gene transfer with allogeneic fibroblasts [Hildebrand et al., 1999] .
Non-viral gene therapy to tendons has been limited to patella tendon models. Initial studies with human papilloma virus (HPV)-liposome-LacZ suspensions injected into rat patella tendons demonstrated staining for marker in less than 10% of cells in healing tendons, but with persistence of the marker gene for up to 8 weeks [Nakamura et al., 1996] . The application of PDGF-BB to haemagglutinating virus of Japan (HVJ)-liposomes led to expression of PDGF-BB for up to 4 weeks post injury with transiently increased angiogenesis and collagen deposition that were no longer detectable at 8 weeks [Nakamura et al., 1998 ]. Transfection efficiencies approaching 100% for β-galactosidase were achieved in an in vivo flexor tendon laceration and repair canine model using DNA/transferrin and cationic liposome addition to permeabilised cells [Goomer et al., 2000] . β-galactosidase staining was detectable in the tendon pulley, sheath and skin, with no evidence of a local immune reaction.
GENE THERAPY IN PERIPHERAL NERVE REPAIR
Peripheral nerves are made up of axons with neurons running in them and are surrounded by myelin sheaths and Schwann cells. These are in turn surrounded by an endoneurium and are grouped together by a perineurium that makes up nerve fascicles. Groups of fascicles are bound together by an epineurium (Fig. 2) [Lawrence and Kashyap, 2000] . Peripheral nerve injuries commonly accompany traumatic hand injuries. The injury results in degeneration of all cellular elements distal to the injured axon. This results in a chemical and cellular breakdown of all neural elements by the formation of proteases and free radicals and the phagocytosis by Schwann cells and macrophages. In response to nerve injury Schwann cells and macrophages also produce cytokines such as nerve growth factor (NGF), IGF, PDGF and apolipoprotein E. As an injured nerve attempts to heal, axons sprout from the proximal end and form a growth cone (axoplasmic enlargement) at the tip of the sprouts. These in turn have filopodia that extend out from the cones seeking a favourable environment, such as those with Schwann cells, fibronectin, laminin and other substances found in endoneural sheaths. Axons will then begin to grow in the favourable substrate and other auxiliary sprouts will degenerate. Cytoskeletal components produced in the cell body of nerves are then transported down the axon to the site of injury to contribute to new axonal growth [Lawrence and Kashyap, 2000] . Neurotropic factors are also released from the denervated tissue and contribute to axonal growth. These include NGF, FGF and ciliary neurotrophic factor (CNTF). Despite the release of these neurotrophic factors, the number of successful axons regenerating is less than the original number. Delay in nerve healing results in the reduction of the size of the distal nerve segment as well as the distal blood supply, reducing the chance of successful nerve regeneration and function [Lawrence and Kashyap, 2000] .
Surgical repair attempts to anatomically realign motor and sensory fascicles as accurately as possible under microscopic magnification. Although labelling of fascicles with acetylcholinesterase for motor and carbonic anhydrase for sensory components has been reported, it is a clinically time-consuming and labour intensive procedure that is not frequently performed [MacKinnon and Dellon, 1988] . Alternatively nerve conduction studies of dissected fascicles can be done intra-operatively but these often require the interpretation of a neurophysiologist. Current clinical practice involves the direct primary repair of lacerated nerves and if this is not possible then nerve grafts harvested from elsewhere are used. Donor sites are carefully chosen to minimise neurological morbidity. Return of function post repair is often incomplete, and can take at least 6 months. Results of nerve repair are compromised in severe injuries that result in tissue scarring and with injury at multiple levels Fig. (2) . Cross-sectional anatomy of a peripheral nerve. of the nerve [Lawrence and Kashyap, 2000] . Gene therapy in combination with surgery, offers the potential to produce a favourable environment for nerves to heal by the delivery of neurotropic factors.
NGF is currently the most studied cytokine with the capacity to stimulate peripheral nerve migration. Other neurotrophic factors include brain derived nerve factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), IGF-1/2, PDGF, FGF and CNTF. Exogenous NGF has been shown to prevent the death of axotomized sensory neurons [Rich et al., 1987] , while NGF recombinant protein has been used to promote the neurotization of denervated muscle by direct nerve implantation [Menders et al., 2002] . Patrick et al. (2001) has performed successful in vitro production of NGF following lipid-based transfection of dermal fibroblasts to mimic Schwann cells. Other groups have delivered neurotrophic factors by using retrovirally transduced fibroblast cells with human NGF to overcome the difficulty in transfecting neuronal cells [Hoffman et al., 1993] . Joung et al., (2000) successfully transduced Schwann cells with adenoviruses in vitro and in vivo, demonstrating LacZ gene expression for 5 weeks, during which nerve regeneration was accomplished in a rat model. In vitro studies of dorsal root ganglia sensory neurons of murine and human origin have demonstrated the successful transduction by recombinant adeno-associated adenovirus (rAAV) and vesicular stomatitis protein G-pseudotyped lentivirus vector derived from human immunodeficiency virus (HIV-1) [Fleming et al., 2001] . The cell bodies of peripheral sensory neurons are clustered within the dorsal root ganglia, which facilitate the delivery of genetic vectors to sensory neurons. Similarly a lentivirus vector system encoding GDNF injected into the facial nucleus of Balb/C mice demonstrated complete protection of axotomized motorneurons following subsequent facial nerve transection [Hottinger et al., 2000] . Herpes simplex virus based vectors expressing GDNF and the anti-apoptotic peptide Bcl-2 prevented neuronal death and enhanced functional recovery in a rodent model of axonal cell death resulting from trauma [Fink et al., 2003] .
GENE THERAPY IN FRACTURE HEALING
Bones of the appendicular and axial skeleton are formed by endochondral ossification and characterised by a cartilaginous phase prior to ossification [Grabb and Smith, 1997c] . In contrast, membranous bone is formed directly from mesenchymal condensations in the cranial vault, facial skeleton and clavicle in embryonic life. Bone healing following injury involves both osteoinduction and osteoconduction. Osteoinduction is the transformation of pluripotent mesenchymal cells into bone cells by means of chemical, humeral and physical signals. Osteoconduction is the ingrowth of capillaries and osteoprogenitor cells into the fracture from surrounding bone and soft tissue. Bone can heal in different ways depending on multiple factors such as the type of bone injured, the vascularity of the injured bone, the severity of the fracture and the immobilisation of the bone ends. Optimal healing results in new bone formation when fractures are adequately reduced and immobilised. Non-optimal healing results in fibrous union with loss of structural bony rigidity, ultimately impeding on function [Lawrence and Kashyap, 2000] .
The three types of bone healing are callus formation in endochondral bones, primary healing in membranous bones and fibrous union in poorly approximated and mobile bone fragments. Endochondral bone formation involves the stages of haematoma and inflammation, soft callus and hard callus formation and remodelling. The initial phase of haematoma and inflammatory cell infiltration is accompanied by bone debris reabsorption. The soft callus formation is immature bone that results from the migration of precursor mesenchymal and osteoprogenitor cells from the periosteum, bone marrow, endosteum and surrounding muscle. These cells differentiate into fibroblasts, chondrocytes and osteoblasts and synthesize different proportions of collagen, cartilage and unmineralized bone. Hard callus formation results from mineralisation of the soft callus. During this phase, type II collagen is replaced by type I collagen and calcium hydroxyapatite crystals are deposited, along with a greater increase in the vascularity of the bone. The last phase of bone remodelling involves the stabilisation of bone infrastructure by cell-mediated breakdown and bone formation [Lawrence and Kashyap, 2000] .
Primary bone healing occurs principally in membranous bones and involves healing without cartilaginous and callus formation. Remodelling begins immediately after new bone bridges the fracture site with type I collagen deposition present from the beginning. Fibrous bony union results in a non-functional cartilaginous scar.
Bone healing is crucial in both hand and craniomaxillofacial surgery. A fracture or osteotomy injury results in the disruption of vasculature, infiltration of inflammatory cells and the release of cytokines including PDGF, TGF-β, BMP, interleukin-1, interleukin-6 and TNF-α. BMP, a member of the TGF-β family has been extensively investigated because of its osteoinductive properties. The application of inducive agents via gene therapy to increase bone healing is attractive, as it has the potential to accelerate healing and the recovery of patients through earlier mobilisation. Baltzer et al. (2000) have administered adenoviral vectors encoding human BMP-2, TGF-β and LacZ in a lapine femoral 1.3 cm segmental defect model, and have shown that animals treated with BMP-2 produced radiographic signs of healing by 5 weeks compared to controls. Histological examination at 8 weeks demonstrated complete ossification in BMP-2 treated animals, while by 12 weeks all experimental defects had healed. Biomechanical testing of femurs confirmed statistically significant higher bending strength and stiffness. Although TGF-β did not produce successful mineralised bridging of experimental defects at 16 weeks, there was histological evidence of increased bone matrix synthesis. The simplicity of adenoviral administration makes this an attractive model, with direct in vivo injection into a chamber made of the surrounding muscle around the internally fixed fracture.
In vivo non-viral gene delivery to bone defects has also been investigated. Fang et al. (1996) and Bonadio et al. (1999) have confirmed the capacity of wound repair fibroblasts to take up plasmid DNA and produce recombinant protein. The authors applied BMP-4 and parathyroid hormone to segmental defects in rodents and canines via a three-dimensional matrix embedded with DNA and demonstrated bone gap bridging not observed in control animals. This approach to gene delivery allows for the prolonged application of bone enhancing genes, avoiding the potential adverse effects of viral vectors and the rapid degradation of directly administered recombinant protein.
Relying on the endogenous fibroblasts to take up the plasmid and produce recombinant protein also bypasses the requirement for complex and laborious ex vivo cell manipulation.
The unique characteristics and clinical importance of membranous bone prompted Steinbrech et al. (2000) to investigate the endogenous expression of genes during membranous bone healing. The authors demonstrated the importance of TGF-β and TGF-β Receptor II in bone repair in an osteotomized mandibular rat model. These genes were maximally expressed at 1 week postoperatively and returned to near normal levels at 6 weeks. The proteins were initially expressed in inflammatory cells and mesenchymal cells in the fracture gap and later detected in osteoblasts in areas of bone matrix deposition and remodelling, suggesting a potential application in the treatment of craniomaxillofacial disorders. At this stage, studies relating to the use of these genes have been limited to the use of recombinant proteins [Sherris et al., 1998; Zellin et al., 1998 ].
TISSUE ENGINEERING
Tissue engineering is an interdisciplinary field that applies the principles of engineering and the life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function [Langer and Vancanti, 1993] . It has become an area of intense research in plastic surgery and other fields of medicine as the interplay between cells, growth factors and supporting matrices is investigated. It is hoped that forming tissue de novo will overcome many problems in plastic surgery associated with such areas as wound healing that lead to dysfunctional repair, and in tissue reconstruction that requires the use of tissue from an alternative site with inevitable donor site morbidity.
The biology of embryonic and adult stem cells is being intensively studied as these cells offer the capacity for selfrenewal and differentiation. At this stage, the use of adult stem cells and particularly autologous cells would be the most readily acceptable form of regenerating cell use in plastic surgery, as it avoids the ethical problems associated with embryonal cell use. The combination of stem cell tissue engineering with gene therapy has the potential to provide regenerative tissue cells within an environment of optimal regulatory protein expression. A major challenge remains the ability to understand the biology of numerous types of stem cells and the environmental cues that are necessary to promote their successful differentiation and expansion. The growth factors necessary for optimal tissue repair may not necessarily be identical to those required for tissue regeneration.
The main areas of investigation of tissue engineering in combination with gene therapy in plastic surgery have been in skin transplantation, cartilage, bone, adipose tissue and blood vessel production and tendon healing. Tissue engineering of skin consists of a bilayer structure with an insoluble dermal extracellular matrix populated by cultured epidermal cells. Integra (Integra LifeSciences Corporation, Plainsboro, NJ, USA) is a commercially available bioengineered skin substitute made of porous bovine collagen and chondroitin sulphate backed by a polymer layer. It has been designed to allow the host fibroblasts to migrate into the matrix and deposit host collagen resulting in a 'neodermis' that replaces the artificial dermis and develops a vasculature that becomes permanently incorporated. The silicone layer acts as a barrier to bacterial contamination and modulates fluid flux [Fitton et al., 2001] . After the neodermis has been vascularized (2-3 weeks), the silicone layer is removed and thin split skin autogenous epidermis is grafted onto the neodermis. Integra has been used as a biological dressing for the coverage of acute large burn wounds and more recently has been used in reconstruction of severely contracted skin post severe burns and traditional split skin grafting [Heimbach et al., 1988; Chou et al., 2000; Hunt et al., 2000; Fitton et al., 2001] .
The clinical application of Integra and other bioengineered skin substitutes have unfortunately not produced consistent optimal results and appear to be very operator dependent [Hunt et al., 2000; Fitton et al., 2001] . Preselection of epithelial stem cells and the use of these cells as carriers of genetic vectors that increases angiogenesis and decreases scar formation may help improve these results. It has been shown that epithelial stem cells need to be preselected prior to bioengineering of skin to maintain the bioengineered epidermis longterm [Dunnwald et al., 2001] . Transduction of such cells with a retrovirus encoding the β-galactosidase marker yielded skin with persistent β-galactosidase expression for 6 months.
Cartilage and bone tissue engineering have been combined with both viral and non-viral gene therapy. Cartilage tissue consists of chondrocyte cells within a matrix of proteoglycans, collagen and noncollagenous proteins. It has no blood supply and obtains its nutrition by diffusion of nutrients in water found in the matrix. The lack of blood supply and decreased metabolic activity means that injury to cartilage may not always result in functional repair [Lawrence and Kashyap, 2000] . Cell based systems have been investigated in vitro and in vivo using periosteal derived stem cells for the repair of osteochondral defects [Grande et al., 2003 ]. These cells have been successfully transduced with retroviral vectors containing BMP-7 or the Sonic Hedgehog gene that are important in the development of the musculoskeletal system. Polyglycolic acid scaffolds with transduced stem cells were applied to full-thickness osteochondral defects in the midtrochlear region of New Zealand white rabbits and observed over a 26-week period. As early as 6 weeks, defects treated with BMP-7 had larger amounts of hyaline cartilage and quicker restoration of the subchondral bone. Sonic Hedgehog transduced stem cells produced the highest quality of hyaline bone but had depleted bone formation in the subchondral compartment. At 12 weeks the subchondral bone was remodelled and the articular surface was of excellent quality. Using a DNA/transferrin-poly-l-lysine/liposome complex with β-galactosidase gene, transfection of permeabilized primary perichondrial cells produced greater than 70% transfection efficiency in vitro [Goomer et al., 2000] . Application of the transfected perichondrial cells in a polylactic acid scaffold and a subsequent rabbit femoral condyle defect produced persistent β-galactosidase expression at 1 week at the surface layer of the implant.
Bone tissue engineering has stimulated a great deal of interest by both orthopaedic and plastic surgeons because of the limitations of bone healing in certain clinical scenarios, such as in severe trauma and in patients with osteoporosis. In such cases, bony reconstruction can involve the use of free bone grafts, vascularized bone grafts or allografts. Alternatively, amputation is the last resort in failed and complicated bony healing of the limbs. Depending on the anatomical location of osseous reconstruction, bone grafts have a tendency to reabsorb and may not withstand successfully the mechanical loads placed upon them. In recent years there has been an increasing number of combined gene therapy and tissue engineering studies, in the hope that genetic vectors may deliver appropriate levels of osteoinducive genes via stem cells to bony areas of reconstruction and enhance the osteogenic potential of stem cells. Whether it is the transduced or transfected stem cells themselves that promote bony growth in scaffolds, or a paracrine effect of delivered genes on endogenous cells has still not been fully elucidated. Bone marrow mesenchymal stromal cells (MSC), myocytes and adipocytes have all been shown to augment osseous tissue healing.
Transduced autologous MSC with BMP-2 combined with a collagen I matrix have been applied to critical size bilateral maxillary defects in a miniature swine model and demonstrated complete osseous healing by 3 months compared to controls [Chang et al., 2003a] . Critical size defects, by definition do not regenerate spontaneously during the lifespan of the animal [Chang et al., 2003b] . Operative examination of the tissue engineered bone, as well as histology and biomechanical testing confirmed that the de novo bone mimicked that of normal bone. Similar results were obtained when transduced MSC with adenovirus BMP-2 construct were combined with collagen I in bilateral critical size cranial defects [Chang et al., 2003b] . Retroviral vectors with BMP-7 have been used to transduce rabbit periosteal cells and then applied to critical-size rabbit calvarial defects within polyglycolic scaffolds [Breitbart et al., 1999] . The calvarial defects treated with transduced periosteal cells produced earlier bone healing at 12 weeks by histology and radiography compared to controls.
Muscle cells have been shown to be a source of osteogenic precursors and under osteogenic conditions in vitro will differentiate into an osteogenic lineage [Yamaguchi et al., 1991; Katagiri et al., 1994] . The use of muscle cells to develop bone is an attractive concept as autologous muscle tissue is readily available, such cells can expand rapidly and are easily transduced and transfected [Blau and Springer, 1995; Svenson et al., 1996] . The application of tissue-engineered bone from muscle tissue is relatively new but has produced promising results. Lee et al. (2001) have demonstrated that transduced muscle cells with BMP-2 can be used to treat calvarial defects of SCID mice and that some of these cells can differentiate into osteoblast in vivo.
Adipose tissue has been shown to contain cells that behave like MSC and when grown in vitro can differentiate into bone, muscle, cartilage and fat [Zuk et al., 2001 , Pittenger et al., 1999 . Adipose tissue is easily accessible and in an abundant supply, making it a very attractive source of stem cells. The transduction of lipoaspirate cells has recently been investigated with AdBMP-2, demonstrating that the cells produce more bone precursors and a faster onset of calcified extracellular matrix compared to transduced bone marrow stromal cells [Dragoo et al., 2003] . Further studies are required to demonstrate whether these findings will translate to the clinical scenario.
Preadipocytes have been identified in adipose tissue and have the potential to differentiate into mature adipocyte cells. Such cells have been studied in the hope that they can be used in adipose tissue engineering to reconstruct a variety of contour defects treated by plastic surgeons. These include soft tissue defects following trauma, congenital abnormalities such as Poland's and Romberg's syndromes and reconstruction following breast surgery. Adipose tissue engineering would also be extremely useful in cosmetic plastic surgery, such as facial rejuvenation and body sculpting. Preadipocytes can be obtained from adipose tissue or lipoaspirates and are easily grown in culture. Different scaffolds such as hyaluronic acid have been either seeded with preadipocytes and shown to produce adipose tissue in vitro [Halbleib et al., 2003] , or Matrigel which has been combined with gelatin microspheres coated with bFGF and implanted subcutaneously in vivo, have resulted in de novo adipogenesis [Tabata et al., 2000; Kimura et al., 2002; Kimura et al., 2003] . It is not certain whether bFGF has a direct effect on adipocytes to promote their differentiation and proliferation or whether bFGF influences the migration of preadipocytes to the newly vascularized Matrigel. Vascularisation of the Matrigel was also greater with the controlled release of bFGF compared to free bFGF. The combination of gene therapy with adipose tissue engineering could similarly provide a method of controlled sustained release of growth factors to the microenvironment of preadipocyte cells.
Preliminary studies using mesenchymal stem cells (MSC) as gene therapy vehicles for tendon repair have also produced favourable results. A one cm gap in an immature rabbit achilles tendon model was bridged with suture material and surrounded with collagen gel and a MSC implant. At 4, 8 and 12 weeks the experimental group had significantly greater structural and mechanical properties of the healing tendon compared to controls, with a significantly larger cross-sectional area, while collagen fibres appeared to be better aligned in the experimental group [Young et al., 1998 ]. Cytokine production by MSC was felt to most likely produce stimulating factors that accelerated tendon healing.
One of the main limitations of tissue engineering is the volume of tissue that can be produced. As a better understanding of the interplay between stem and mature cells and the growth factors that are necessary to promote their migration, differentiation and proliferation in scaffolds is obtained, the role of gene therapy in tissue engineering will expand and become increasingly important.
CRANIOSYNOSTOSIS
The molecular mechanism of craniosynostosis, the premature fusion of one or several cranial sutures, is incompletely understood. Over 100 syndromes have been reported [Wilkie, 1997] . The dura mater beneath the cranial suture regulates the fate of the suture [Bradley et al., 1997] . Patent and fused sutures have different patterns of cytokine expression, with upregulation of osteogenic cytokines and bone extracellular matrix molecules in a murine model of programmed cranial suture fusion [Greenwald et al., 2000] . The regional differentiation of suture-derived dural cells was maintained in culture conditions and was demonstrated to modify the cellular proliferation rate of osteoblasts. Greenwald et al. (2000) propose that this differentiation effect occurs in vivo and that extracellular matrix deposition regulates sutural fate. Programmed-to-fuse associated dura mater expressed higher levels of TGF-β1 and TGF-β3 compared to the sagittal which remained patent, while increased levels of collagen I, collagen III, alkaline phosphatase and osteocalcin mRNA were documented. TGF-β is associated with increased bone deposition and induces collagen deposition. Mehrara et al. (2002) investigated the use of an adenoviral defective type II TGF-β receptor as potential therapy for craniosynostosis. This adenovirus could block TGF-β biological activity. They harvested posterior frontal sutures from the programmed to fuse mouse model prior to initiation of suture fusion and infected the dura mater with the adenovirus. The sutures were then cultured in vitro and at 14 days, the adenoviral defective type II TGF-β receptor had attenuated suture fusion compared to the adenovirus LacZ control. The findings strongly implicated TGF-β in the regulation of programmed sutural fusion.
Mutations in three of the FGF receptors (FGF-R1, FGF-R2 and FGF-R3) have been associated with syndromic craniosynostosis patients. The mutations lead to intracellular gain-of-function activity either by the formation of tyrosine kinase receptor dimers and subsequent ligand independent signalling or by increasing receptor affinity for ligand. Gainof-function mutations in FGF-R2 are thought to lead to premature fusion of cranial sutures and dysmorphic features, and have been associated with numerous congenital disorders including Apert syndrome, Crouzon syndrome, Pfeiffer syndrome and Jackson-Weiss syndrome [Witt and McArthur, 1998 ]. The critical role of FGF in programmed and pathological cranial suture fusion has been confirmed in animal studies [Greenwald et al., 2001] . Adenoviruses with the truncated form of FGF-R1 and a secreted form of FGF-2 were applied to the dura mater underlying the programmed to fuse and patent sutures respectively of embryonic rats. The in utero application of the adenoviral vector encoding a truncated form of FGF-R1 into the programmed to fuse suture of rats was able to attenuate suture fusion. This adenovirus has been shown in vitro to inhibit signal transduction of FGF-R1, FGF-R2 and FGF-R3. The adenovirus encoding FGF-2 was applied in utero into the coronal suture of rats that normally remains patent. Fusion of this suture occurred at postnatal day 30, and was accompanied by elevated levels of osteocalcin and alkaline phosphatase, both of which are markers of osteoblast differentiation. Increased expression of alkaline phosphatase and osteocalcin in sutures is also seen in patients with craniosynostosis associated with Apert syndrome. This study confirms that suture fate is related to FGF biological activity and suggests the possibility that targeted in utero gene therapy with truncated FGF-R1 could be used to prevent programmed postnatal sutural fusion. In utero gene therapy however, will only become a reality when gene delivery systems are greatly improved.
HAEMANGIOMAS
Proliferating haemangiomas are benign vascular endothelial cell tumours that typically appear in the neonatal period. They are characterised by a proliferating phase where cells have a high rate of mitosis and an involuting phase where highly mitotic cells gradually diminish and are replaced by endothelial cell apoptosis. The former usually occurs during the first 6-8 months of infancy and the involuting phase results in regression between the ages 5-10 years. The incidence in Caucasians of cutaneous haemangiomas is 5-10%. Large haemangiomas may be problematic and possibly life-threatening. They can cause obstruction, ulceration, bleeding, pain and high output cardiac failure [Mulliken and Young, 1988] .
Haemangiomas are clonal expansions of endothelial cells caused by somatic mutation of one or more genes [Boye et al., 2001] . Walter et al., (2002) identified mutations in the kinase domains of Flk-1 and Flt-4 receptors for VEGF in two of fifteen haemangiomas resected from infants. The authors postulate that alterations of the VEGF signalling pathway may initiate clonal expansion of haemangioma formation, and speculate amplification primers may have obscured somatic deletions underlying the primers in other specimens.
Alternatively, extrinsic upregulation of angiogenesis by cytokines such as VEGF and FGF may contribute to haemangioma formation. Proliferating haemangiomas have been found to express angiogenesis activators such as VEGF-A [Chang et al., 1999] . Upregulation of VEGF-A and bFGF mRNA in proliferating lesions has been identified in endothelial cells and pericytes. Involuting specimens have high levels of TGF-β1 together with metalloproteinases (MMP), tissue inhibitors of metalloproteinase-1 (TIMP)-1 and IFN-β Bielenberg et al., 1999] . There is also recent evidence to suggest that hemangiomas may be derived from embolized endothelial cells of placental origin or from precursors dislodged into the fetal circulation [North et al., 2000] . Extrinsic influences or somatic mutations that switch postnatal endothelial cells to an immature phenotype have also been proposed as explanations for placental features in haemangioma-derived tissue [North et al., 2001] .
Kasabach-Meritt Syndrome is a life-threatening complication of haemangioma-like tumours in infants. Rapidly enlarging haemangiomas result in platelet trapping, profound thrombocytopenia and prolonged prothrombin time, activated partial thromboplastin times and hypofibrinogenaemia. Lesions are usually detected postnatally and pose a great risk of haemorrhage. Despite aggressive systemic corticosteroid therapy between 20-50% of infants die secondary to bleeding complications. In vivo interleukin-12 (IL-12) gene delivery to a mouse model of Kasabach-Merritt syndrome using a gene gun prevented the rapid growth of primary vascular tumours and increased mouse survival . The authors successfully showed that IL-12, a potent anti-tumour and anti-angiogenic agent could be easily, rapidly and painlessly delivered by a gene gun to skin and that localised epidermal expression of IL-12 was sufficient to amplify the mouse's anti-tumour immune response avoiding the need for systemic corticosteroid or IFN-α therapy.
Other therapeutic agents that have been investigated for their ability to produce regression in haemangiomas in animals include Angiostatin, Batimastat (a synthetic inhibitor of MMP) and TIMP-2 [Taraboletti, et al., 1995; Lannutti et al., 1997; Vergani et al., 2001] . Incorporation of genes for these inhibitors into vectors represents a further avenue in the treatment of haemangiomas. An understanding of the molecular profile and genetic control of hemangioma formation will lead to the development of nonsurgical treatment specifically targeting endothelial dysfunctional growth and augmenting involution.
HEAD AND NECK CANCER
Advanced squamous cell carcinoma of the head and neck (SCCHN) region is a difficult therapeutic challenge with a locoregional recurrence rate of 50% despite combination therapy with surgery, radiotherapy and chemotherapy. These patients are left with few options for further treatment and have a poor prognosis, making them appropriate candidates for novel therapies. In many countries, plastic surgeons are involved in both the resection and reconstruction of surgical defects of head and neck tumours. As such the biology and the potential role of gene therapy in the treatment of these cancers is important. Mutations in tumour suppressor genes p53, p16, p21, p27 and retinoblastoma (Rb) and oncogenes cyclin D1, epidermal growth factor (EGF) and its receptor (EGF-R) and STAT3 have been identified in head and neck squamous cell carcinomas [Gerich et al., 1996] . The most intensively investigated mutated gene is p53. Wild-type (normal) p53 is a tumour suppressor gene and inducer of cell cycle arrest and apoptosis. Although several studies have demonstrated clonal mutations at SCCHN tumour margins, the predictive value of p53 mutations for tumour recurrence is controversial, with other studies identifying no correlation [Brennan et al., 1995; Koch et al., 1996; Hogmo et al., 1999; Saunders et al., 1999] . Nevertheless, preclinical in vitro and in vivo studies using recombinant adenovirus with wild-type p53 (Adp53) have induced apoptosis in various head and neck tumour cell lines, reduced the growth of established tumours and prevented the establishment of microscopic tumours following subcutaneous injection of SCCHN cell lines in xenografted animals . A phase I clinical trial in patients with advanced locoregionally recurrent SCCHN demonstrated the safety of Adp53 as an adjuvant therapy [Clayman et al., 1999] . Of the 33 patients entered into the clinical trial, 15 patients with advanced locoregionally recurrent or refractory SCCHN were placed into the surgical arm. This meant that the patients' tumour could be surgically resected to microscopic residual disease, but resection offered no or little opportunity for cure. Pre-, intra-and post-operative local administration of Adp53 in the 15 patients with oral recurrences achieved a median survival of 12.4 months, with 4 (27%) patients remaining disease-free with a median follow-up of 18.25 months. This median survival of 12.4 months is reported to be approximately 60% longer than that found in chemotherapy trials in similar patients [Clayman et al., 1999] . It is thought that the Adp53 may decrease residual disease at surgical margins of SCCHN that are molecularly detectable by PCR but not macroscopically visible. International phase II trials are currently underway ( Table 1 ).
The encoded protein (Rb94) of the retinoblastoma gene inactivates a transcription factor responsible for cell cycle progression, resulting in cell growth suppression. Li et al., (2002) have transduced human squamous cell carcinoma lines with an adenovirus containing Rb94 (AdRb94) and subsequently injected nude mice xenografts with the cell lines. The protein encoded by the Rb94 gene significantly suppressed tumour cell growth both in vitro and in vivo, demonstrating cell cycle arrest and induction of in vivo apoptosis.
Epidermal growth factor receptor (EGF-R) regulates the growth of the epithelial cells on which it is found following interaction with EGF and TGF-α . EGF-R is expressed in primary SCCHN tumours. Although antisense EGF-R sequences administered to a SCCHN xenograft mouse model in combination with a liposome complex resulted in inhibition of tumour cell growth [He et al., 1998 ], subsequent toxicity studies in mice demonstrated that EGF-R antisense gene therapy only resulted in self-limited inflammation at the injection site [Zeng et al., 2002] . A phase I clinical trial is currently underway in patients with advanced HNSCC [Zeng et al., 2002] .
ONYX-015 is an adenovirus from which the E1B 55kD region necessary for the binding and inactivation of p53 has been deleted. It was initially thought that this adenovirus was unable to replicate in normal cells that retained their p53, but was able to replicate and was cytopathic in tumour cells that have lost their p53 function [Bischoff et al., 1996] . More recently it has been shown that the cell-selectivity of this adenovirus for tumour cells is not controlled by the p53 or p14 ARF (positive regulator of p53) [Edwards et al., 2002] . Despite the lack of understanding of the selective mechanisms of ONYX-015, animal models suggest the efficacy of the virus is augmented by standard chemotherapeutic regimens [Xi and Grandis, 2003] . Phase I and II trials have demonstrated that ONYX-015 can be administered safely intra-tumourly into patients with advanced head and neck cancer, although only moderate tumour responses have been observed Nemunaitis et al., 2001] . A phase II trial that investigated the combination of ONYX-015 with cisplatin and 5-fluorouracil in 37 patients with recurrent head and neck cancer showed a partial response in 15 patients [Khuri et al., 2000] . All of the responders remained free of progression at six months. A formal randomised trial will be required to confirm these positive findings.
CONCLUSION
Gene therapy in plastic and reconstructive surgery remains experimental. Progress will depend on a better understanding of the molecular basis of the process of tissue healing and tumour biology and on improved delivery systems. Tissue engineering is an area of intense research in plastic surgery and will most likely be applied in clinical practise in the future. We believe that gene therapy will play an important role in overcoming some of the limitations of tissue engineering that have been encountered so far. With the exception of head and neck cancer, most patients in plastic surgery do not have life-threatening illnesses. As such, the application of gene therapy is likely to continue to follow on from experiments and clinical trials in other areas at this stage. 
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